← Back to all trials
Not Yet Recruiting
NCT07643038
Treatment Strategy for Patients With RA-ILD
Conditions: Rheumatoid Arthritis Associated Interstitial Lung Disease
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 204
Sponsor: Chinese SLE Treatment And Research Group
Location: The First Affiliated Hospital of Henan University of Science and Technology Luoyang Henan
Summary
This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.
Eligibility Criteria
Inclusion Criteria:
* Fulfillment of the 2010 ACR/EULAR classification criteria for RA.
* HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.
* Pulmonary function impairment defined as forced vital capacity (FVC) \
Source: ClinicalTrials.gov (NCT07643038). StuddyBuddy aggregates publicly available trial information.
